What Are the City's Expectations for AstraZeneca's Profits?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

LONDON -- When weighing up a potential investment, we always need to look forward rather than backward.

If you buy a stake in a business, it's the future profits that count -- and the stock market will value your shares based on future expectations.

With that in mind, it can be helpful to review what expert City analysts are expecting a company to earn in the coming years. These expectations can then be compared to the share price to give you a better idea of how the stock market is valuing the business.

Today, I'm looking at the earnings per share forecasts for AstraZeneca  (LSE: AZN  ) (NYSE: AZN  ) , the FTSE 100 pharmaceutical giant. All my figures are courtesy of S&P Capital IQ.

Analysts expect AstraZeneca's profits to be 3.34 pounds per share this year. This estimate means that, compared to today's share price of 3,296 pence, the market is valuing AstraZeneca's shares on a forward price-to-earnings multiple of 9.8.

Looking ahead, the consensus then calls for a further decline in AstraZeneca's earnings to 3.19 pounds per share for 2014, before slipping to 3.15 pounds in 2015. The data also indicates that AstraZeneca's revenues might shrink by almost 7% a year over the same time period, from $30 billion to around $24.7 billion.

These damp expectations explain why AstraZeneca's shares appear to trade on such a lowly valuation. But with a new management team in place, could the company find a way to revive its pipeline of new treatments, or is AstraZeneca cheap for a reason?

Of course, whether these questions, the City's profit projections, and the current valuation make the shares of AstraZeneca a buy, hold, or sell is for you to decide.

But if you already own shares in AstraZeneca and are looking for similar, high-quality investment opportunities, I've helped pinpoint five particularly attractive possibilities in this exclusive wealth report.

All five companies offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as "5 Shares You Can Retire On"!

Just click here to download your exclusive free report.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2485777, ~/Articles/ArticleHandler.aspx, 9/26/2016 12:16:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,117.29 -144.16 -0.79%
S&P 500 2,149.43 -15.26 -0.70%
NASD 5,264.08 -41.67 -0.79%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 11:55 AM
AZN $5112.39 Down -57.61 -1.11%
AstraZeneca CAPS Rating: No stars
AZN $33.58 Down -0.39 -1.15%
AstraZeneca CAPS Rating: ****